Apotex announces grant to Healthy Mothers, Healthy Babies Coalition of Broward County to promote maternal health with $242,000 in annual funding
Feb 13, 2025Weston, Florida – February 13, 2025 – Apotex Inc. (“Apotex”), the largest Canadian-based pharmaceutical company, today announced a grant through the Apotex Global Health Access Fund to Healthy Mothers, Healthy Babies Coalition of Broward County (“HMHB/Broward”) in Lauderhill, Florida, to support programs that promote maternal health and address health disparities.
Building on Apotex’s legacy of giving, including Apotex’s global medicine donation program, the Apotex Global Health Access Fund focuses on addressing unequal access to care and low health literacy within communities where there are poor social determinants of health. Apotex’s US headquarters are located in Weston, Florida.
HMHB/Broward is the second Apotex Global Health Access Fund grant recipient, and the first in the United States. The organization will receive $242,000 annually over the next three years to support the Mahogany Project, which provides comprehensive maternal health services to high-risk pregnant women in Broward County, aiming to improve birth outcomes and address social determinants of health.
“We are thrilled to announce this grant to Healthy Mothers, Healthy Babies, which underscores our commitment to addressing health disparities,” said Christine Baeder, President of Apotex USA. “By supporting initiatives like the Mahogany Project, we aim to make a significant impact on maternal health and the well-being of families, supporting people on their health journeys.”
“We are incredibly grateful to Apotex for their commitment to our mission,” said Dawn Liberta, Executive Director of HMHB/Broward. “This support could not have come at a better time, as it will help us expand our reach and enhance the services we provide in helping reduce maternal and infant mortality in Broward County.”
In its inaugural year, the Apotex Global Health Access Fund focuses on funding maternal health programs in Canada, the United States, India, and Mexico with an annual budget of $1 million. The first grant recipient was the Rexdale Community Health Centre in Toronto.
For more information about Healthy Mothers, Healthy Babies, please visit www.hmhbbroward.org.
About Apotex
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
May 25, 2025
Apotex launches nilotinib capsules, the first generic version of Tasigna®¹ in the United States, with 180 days of exclusivity
Nilotinib is a kinase inhibitor indicated to treat certain types of leukemia, including newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia ("Ph+ CML") in chronic phase in adults and children aged 1 year and older. It is also indicated for adults and pediatric patients with chronic or accelerated phase Ph+ CML with resistance or intolerance to prior therapy, demonstrating higher efficacy compared with other available treatments.
-
May 20, 2025
Apotex publishes 2024 Sustainability Report, highlighting progress and achievements in environmentally sustainable manufacturing, responsible business practices, and social impact
Apotex's 2024 Sustainability Report underscores our commitment to advancing health and unlocking new possibilities through partnerships, while championing sustainability and responsible business practices. "As we continue to execute our Journey of Health growth strategy, our focus on sustainability ensures that we are meeting the needs of patients, physicians, and pharmacists, and contributing positively to the environment and society. This report reflects our dedication to these values, and to transparency, accountability, and long-term value creation," said Allan Oberman, President & CEO, Apotex.
-
May 9, 2025
Apotex introduces IVRA™ (Melphalan) hydrochloride injection: First ready to dilute liquid formulation of Melphalan injection approved via 505(b)(2) NDA in the United States
Weston, Florida (May 09, 2025) – Apotex Corp. today launched IVRA™ (Melphalan) hydrochloride injection 90mg/ml multidose vial ("IVRA"), first ready-to-dilute liquid formulation of Melphalan injection approved via 505(b)(2) NDA in the United States.